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M. Ledson1, M. Walshaw1. 1Liverpool Heart and Chest Hospital NHS Trust,
CF Unit, Liverpool, United Kingdom
TSI is recommended for CF patients chronically infected with Pseudomonas
aeruginosa, since it improves lung function and reduces pulmonary exacerbations.
Despite this, its uptake (both TOBI® and isotonic Bramitob®) in the UK is poor.
To study this, we surveyed 30 specialist UK CF centres, looking at reasons for TSI
use, type and regime used, funding issues, whether a trial of therapy was considered
and side-effects (SEs): 23 (77%) responded.
Although 16 (70%) used TSI, 12 (75%) only did so when nebulised colomycin
failed or was not tolerated. Of these, 10 (65%) only used TOBI® and of those
6 who used both, Bramitob® was ﬁrst line in 1 (17%). As regards prescription,
13 (57%) followed the licensed alternate month regime, 2 (9%) alternated with
colomycin, and the remainder a variable frequency including continuous use.
TSI was funded by primary care in 13 (57%), secondary care in 3 (13%), but the
remainder were unclear. Funding was dealt with by the pharmacy in 9 (39%), the
ﬁnance team in 3 (13%), and in 3 (13%) by the CF team. As regards a therapy
trial, 11 units did so with objective measures, but only 2 units carried out reviews
at 3 and 6 months respectively. Overall, TSI tolerability was good but common SEs
included; bad taste, chest tightness, bronchoconstriction and haemoptysis: these
were more common with TOBI®.
Throughout the UK there seems to be a wide variation in the use of TSI in CF
units, and funding streams are not clear − this is particularly worrying considering
its cost. Since more expensive nebulised therapies are likely to become available in
the near future, a coordinated approach to their use and funding is merited within
the CF community.
162 Effect of saline concentration on the minimum inhibitory
concentration of colistimethate sodium and tobramycin
R. Potter1, R.H.M. Hatley1. 1Philips Respironics, Respiratory Drug Delivery UK,
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Hypertonic saline has been used to facilitate the clearance of mucus from the
lungs in patients with cystic ﬁbrosis (CF). Part of the clinical beneﬁt attributed
to hypertonic saline might be due to NaCl affecting motility and growth of
P. aeruginosa. The aim of this study was to determine the effect of NaCl upon the
minimum inhibitory concentration (MIC) of colistimethate sodium and tobramycin.
P. aeruginosa or E. coli were used with iso-sensetest broth to prepare inoculum
solutions. The broth contained 0.3% NaCl, the lowest concentration of NaCl used
in the tests. Sterile tubes were prepared with the concentration ranges, 128−0mg/L
for colistimethate sodium and 32−0mg/L for tobramycin, with added NaCl con-
centrations of 0.3%, 0.9%, 2.3% or 4.05%. An inoculum of either P. aeruginosa
or E. coli was added and the tubes then incubated at 35−37ºC for 18−20 h. This
process was performed in triplicate for each antibiotic/NaCl/bacteria combination.
The addition of NaCl to the test solution had a synergistic effect on the MIC of
colistimethate sodium needed to prevent growth of P. aeruginosa at the 4.05%
concentration and E. coli at all concentrations. NaCl had an antagonistic effect on
the MIC of tobramycin at all concentrations; this was most marked against E. coli.
The addition of NaCl to the growth environment had a synergistic effect upon
the MIC of colistimethate sodium against P. aeruginosa and E. coli growth, in
contrast to an antagonistic effect upon the MIC of tobramycin. The effect was
concentration dependent for both bacteria. These results may have implications for
the timing of inhaled saline-based treatments in patients with CF using certain
antibiotic formulations.
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eFlow®rapid and PARI LC SPRINT® nebuliser
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Aims: This study reports on in-vitro delivery performance data of Coliﬁn® (1
and 2 million I.U. colistimethate sodium) by the eFlow®rapid, and the PARI LC
SPRINT® nebuliser most recently approved via a decentralized approval procedure
(DCP) in the United Kingdom, Netherlands, and Germany.
Methods: In-vitro nebulisation efﬁciency of 1 and 2 million I.U. Coliﬁn supplied
by PARI Pharma, Starnberg, Germany, dissolved in 3ml and 4ml saline, each,
was investigated by breath simulation tests mimicking an adult breathing pattern
(15 breaths/min, 500ml tidal volume, inh:exh = 1/1) and aerodynamic particle
size assessment by a next generation impactor operated at 18ºC and controlled
environmental conditions at 23±2ºC, 50±5% r.H. and a ﬂow rate of 15 l/min.
Sample solutions were assayed by a validated HPLC-method and UV detection. The
Delivered Dose (DD), Respirable Dose (RD) = drug in droplets <5 and 3.3 mm,
Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation
(GSD) were calculated by the Copley CITDAS Version 2.0 software. All tests were
carried out with 3 nebulisers in quadruplicate (n = 12 each) using the PARI LC
SPRINT powered by a PARI BOY S compressor and the eFlow rapid.
Results: See the table.
Summary of aerosol characteristics (n = 12, values are mean±SD)
DD Neb. time RD [mg] MMAD GSD
[mg] [%] [min] <5mm <3mm [mm]
LC SPRINT 1mio IU 26.7±3.6 33.7±4.5 6.2±1.0 15.9±2.4 10.2±1.6 4.0±0.4 2.2±0.1
LC SPRINT 2mio IU 65.7±3.6 41.6±2.2 11.0±0.7 39.2±2.9 24.6±2.2 4.1±0.2 2.1±0.1
eFlow®rapid 1mio IU 26.6±2.9 33.6±3.6 3.8±0.3 17.6±2.0 8.0±1.0 4.1±0.1 1.6±0.0
eFlow®rapid 2mio IU 57.8±2.8 36.6±1.7 6.2±0.7 39.9±2.0 18.2±1.5 4.0±0.1 1.6±0.0
Conclusions: DDs and RDs were comparable for the PARI LC SPRINT and
eFlow®rapid. However, nebulisation time was shorter for eFlow®rapid helping
to improve both, quality of life of CF patients and most probably drug adherence,
as well.
164 Tolerability of nebulised vancomycin in adults with cystic ﬁbrosis
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Background: Our standard protocol for eradication of MRSA from respiratory
culture, in adults with cystic ﬁbrosis (CF) includes nebulised Vancomycin 250mg
twice daily for ﬁve days. All patients are pre-treated with a bronchodilator and have
pre and post lung function to ensure that the drug is tolerated.
Method: We performed an audit on all patients with ﬁrst isolation of MRSA
between January 2006 and January 2010 to establish the tolerability of nebulised
vancomycin in this patient group.
Results: A total 22 patients (median (range) age 26.0 (18.5–46.3) years; FEV1 52%
(27–108), had been eligible for treatment over the study period. One patient refused
treatment, another received IV antibiotics instead of standard eradication therapy
due to co-existing respiratory exacerbation, while a further patient was not tested
due to multiple intolerance to other nebulised antibiotics. Out of 19 patients who
received a test dose of vancomycin (250mg) post bronchodilator, only one was
intolerant (FEV1 −21%; FVC −30%; FEF25−75 −10%) and did not commence
therapy. The remaining 18 patients tolerated the test dose (see table 1) and
subsequently completed 5 days of treatment.
Table 1
median (range)
FEV1 0% (−11% to +10%)
FVC −2% (−29% to 33%)
FEF25−75 −1% (−30% to +21%)
Discussion: Nebulised vancomycin appears to be well tolerated although signiﬁcant
bronchoconstriction can occur in some patients. It is important to administer a test
dose and monitor respiratory function before commencing treatment.
